Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH?

Impact · against what's priced in

The article provides no new catalysts for the mentioned healthcare stocks, as it simply lists them as top holdings in ETFs and reports trailing performance. Since the market already assumes the growth trajectories and dominance of these large-cap pharma and biotech names, the content is not material to their valuations.

JNJ+0.00

Already priced in

The price assumes

the current 20.9% free cash flow margin